Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1809 results
August 2020
-
Media Release
Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar® + Mekinist® in advanced melanoma
Phase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanoma Tafinlar + Mekinist remains an effective treatment option based on previously reported… -
Story Discovery
Building collaborations to fight a pandemic
Jennifer Leeds offers a behind-the-scenes look at the consortia forming to address COVID-19.
-
Key Release
FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple… -
Key Release
Novartis announces US District Court for the District of Delaware upholds validity of Gilenya® (fingolimod) dosage regimen patent
Basel, August 17, 2020 — Novartis welcomes the decision by the US District Court for the District of Delaware to uphold the validity of the Gilenya® (fingolimod) dosage regimen patent, as our… -
Statement
Novartis appoints Marc Boutin as Global Head of Patient Engagement & Advocacy
Novartis has appointed Marc Boutin as Global Head of Patient Engagement & Advocacy. He will join Novartis no later than November 1, 2020.
-
Story Access to Healthcare
Ensuring medicine supply to patients during COVID-19
Read how two sites within the Novartis Technical Operations (NTO) network ensured business continuity at scale and speed in the midst of the COVID-19 pandemic.
-
Media Release
Novartis receives EC approval for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps
EC approves Xolair® (omalizumab) as an add-on therapy for severe chronic rhinosinusitis with nasal polyps, the first anti-immunoglobulin E antibody approved in this indication1 Chronic… -
Media Release
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis1… -
Media Release
Novartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma
Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate Kymriah previously… -
Media Release
Novartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasis
EU approval is based on two Phase III studies showing Cosentyx® provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile1 …
July 2020
-
Story Discovery
Collaborating to explore new gene regulation therapies
Novartis and Sangamo Therapeutics plan to pursue potential treatments for neurodevelopmental diseases.
-
Media Release
Novartis receives Piqray® approval in Europe – the first and only targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation
Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation, underscoring Novartis commitment to reimagining cancer care Approval based on SOLAR-1 Phase III trial…